NONOF Stock DD Novo-Nordisk A/S 08/12/2014 12:46:38

New Post Public Reply Private Reply Replies (0) Message Board

Aug 12, 2014 at 1:46 PM

NONOF Novo-Nordisk A/S $NONOF Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=NONOF&am...mp;yt0=Go!

Last Updated: 08/12/2014 12:46:33

Current Price and Quotes
Last Price 44.85
Previous Close 44.50 Open 44.85
Daily Range 44.85 - 44.85 52wk Range 35.65 - 185.05
Volume 20,179 Dividend N/A
Average Vol (30d) 10,474 Yield N/A

Financials
Period Ending Dec 31, 2012 Dec 31, 2011
Total Revenue 13,788,000 11,588,000
Cost of Revenue 2,379,000 2,199,000
Gross Profit 11,408,000 9,389,000
Operating Expenses

Research and Development 1,926,000 1,682,000
Sales, General and Admin. 4,274,000 3,800,000
Non-Recurring Items - -
Other - -
Operating Income 5,208,000 3,908,000
Income From Continuing Operations

Add'l Income/Expense Items 22,000 90,000
Earnings Before Interest and Tax 5,230,000 3,997,000
Interest Expense 316,000 168,000
Earnings Before Tax 4,914,000 3,829,000
Income Tax 1,127,000 843,000
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations 3,787,000 2,986,000
Non Recurring Events

Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income 3,787,000 2,986,000
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders 3,787,000 2,986,000

Recent News

Aug 11, 2014 Sponsor And CRO Finalists Announced For Annual Society For Clinical Research Sites Eagle Award
Aug 8, 2014 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 7 August 2014
Aug 7, 2014 Novo Nordisk A/S: Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014
Aug 6, 2014 Novo Nordisk A/S: Share repurchase programme
Jul 28, 2014 Novo Nordisk A/S - Share repurchase programme
Jul 25, 2014 Novo Nordisk A/S: Novo Nordisk receives positive opinion on Xultophy(r) (IDegLira) from the European regulatory authorities
Jul 22, 2014 Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com
Jul 18, 2014 Global Type 1 Diabetes Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Co, Novo Nordisk and Sanofi-Aventis
Jul 17, 2014 Health Care Sector Stocks Technical Review: Valeant Pharma, Teva Pharma Industries, Novo Nordisk, Curis, and Amarin
Jul 14, 2014 CORRECTION: Novo Nordisk A/S: Novo Nordisk A/S - Share repurchase programme

1
2
3
4
next >